GE HealthCare CleaRecon DL for CBCT Imaging Launched in United States and Europe

May 21, 2025—GE HealthCare recently announced the launch of CleaRecon DL in the United States and European Union. The technology, which recently received FDA 510(k) clearance and CE Mark approval, will be available for use on the company’s Allia platform of interventional image-guided systems.

According to GE HealthCare, CleaRecon DL is powered by a deep-learning algorithm to improve the quality of cone-beam CT (CBCT) images. The artificial intelligence–driven solution is designed to remove streak artifacts caused by the pulsatile nature of blood flow in the arteries and changes in the distribution of contrast during CBCT acquisitions in liver, prostate, neuro, and endovascular aortic repair procedures.

“CleaRecon DL takes CBCT to the next level, enabling clinicians to confidently use CBCT on patients with tools that help us provide the highest quality imaging and treatment across a wide range of clinical scenarios,” commented Charles Nutting, DO, in GE HealthCare’s press release.

Dr. Nutting, an interventional radiologist at Image Guided Therapy in Denver, Colorado, added, “This advancement improves our ability to perform precise interventions, with less manipulation of the image, and eliminates artifacts that have historically hindered image clarity, ultimately helping improve the care clinicians can provide to patients.”